NCT05316116终止早期 1 期
A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Male or female, aged >/=
- •Meet the diagnosis criteria of LGLL as below:
- •a. For a patient with treatment-naive LGLL, peripheral blood needs to have CD3+ CD57+ cells >400/mm³ or CD8+ cells >650/mm³, and, evidence for clonal T cell receptor gamma or beta gene rearrangement by PCR needs to be detected in either peripheral blood or bone marrow.
- •b. For patients with an established diagnosis of LGLL who have been previously treated, multicolor flow cytometry should identify a residual CD3+CD57+CD8+ LGLL population in peripheral blood or bone marrow, and, evidence for clonal T cell receptor gamma or beta gene rearrangement by PCR needs to be detected in either peripheral blood or bone marrow. There is no requirement that peripheral blood absolute clonal CD3+ CD57+ or CD8+ LGLL populations need to reach predetermined minimal value for eligibility since immunosuppressive therapy can significantly decrease LGLL cell count without any impact on neutropenia, anemia or thrombocytopenia which are major causes of morbidity and mortality
- •Has at least one of the indications for treatment:
- •severe neutropenia less than 500/mm³, OR
- •neutropenia associated with recurrent infection, OR
- •symptomatic anemia with Hemoglobin < 9 g/dL, OR
- •transfusion-dependent anemia with transfusion needs >= 1 u per month, OR
- •severe thrombocytopenia <20,000/mm³, OR
- •thrombocytopenia <50,000/mm³ with bleeding.
- •Participant can be treatment-naïve or previously treated for LGLL.
- •Participant currently receiving therapy must have a wash-out period of ≥ 30 days or 5 elimination half-lives, whichever is longer, prior to study drug administration.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Creatinine clearance (CLCr) ≥15 mL/min.
- •If a participant has chronic liver disease, Child-Pugh score needs to be either A or B.
- •For females of reproductive potential: use of highly effective contraception for at least 1 month prior to study drug infusion and agreement to use highly effective contraception during study participation and for an additional 3 months after the last dose of study drug.
- •For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 3 months after the last dose of study drug. Men must agree to not donate sperm during the same period.
排除标准
- •Any active infection requiring systemic therapy, including viral infections such as HIV, Hepatitis B, and/or Hepatitis C.
- •Current use of methotrexate, cyclophosphamide, or cyclosporine for any medical conditions.
- •Has coexisting myelodysplastic syndrome (MDS).
- •Elevated LGL due to viral infection.
- •Pregnancy or lactation.
- •Known severe allergic reactions to siltuximab.
- •At increased risk for Gastrointestinal (GI) perforation, in the opinion of the study investigator.
- •Received live vaccine 30 days prior to study drug administration or Intend to receive live vaccine during treatment period and within 3 months after last dose of study drug.
- •Rheumatological conditions such as rheumatoid arthritis (RA) are not exclusion criteria for the study.
- •Coexisting hematological conditions such as autoimmune hematological anemia (AIHA) or immune thrombocytopenia (ITP) are not automatic exclusion criteria but will be at discretion of study investigator.
- •Previous or concurrent malignancies not considered cured, except inactive non-melanoma skin cancer, in situ carcinoma of the cervix, early-stage prostate cancer, or other cancer deemed clinically insignificant by the Investigator.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the study Investigator.
研究组 & 干预措施
Siltuximab
Experimental
Siltuximab will be given every 3 weeks, for between 18 and 36 weeks
干预措施: Siltuximab (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: Up to 30 months
Overall response rate is defined as the rate of achieving best response of CR or PR, and will be summarized for participants who have received any dose of study drug
次要结局
- Time to Response (TTR)(Up to 30 months)
- Complete Response Rate (CR)(Up to 30 months)
- Duration of Response (DOR)(Up to 30 months)
- Duration of Complete Response(Up to 30 months)
- Time to Complete Response(Up to 30 months)
- Duration of Complete Response with Normalization of PB LGL Count(Up to 30 months)
- Progression Free Survival(Up to 30 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory ComplicationsSevere Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 InfectionNCT04322188A.O. Ospedale Papa Giovanni XXIII220
已完成
2 期
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSPrimary Focal Segmental GlomerulosclerosisNCT01573533Mayo Clinic9
已完成
2 期
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's DiseaseMulticentric Castleman's DiseaseNCT01400503Janssen Research & Development, LLC60
已完成
1 期
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal EncephalitisRasmussen's EncephalitisChronic Focal EncephalitisNCT00259805California Pacific Medical Center Research Institute10
已完成
2 期
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaHigh-risk Smoldering Multiple MyelomaNCT01484275Janssen Research & Development, LLC85